Pluri Inc. Signs Material Definitive Agreement
Ticker: PLUR · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1158780
| Field | Detail |
|---|---|
| Company | Pluri Inc. (PLUR) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001, $10,000,000, $1,250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Pluri Inc. signed a big deal on 6/12, details TBD.
AI Summary
Pluri Inc. announced on June 18, 2024, that it entered into a material definitive agreement on June 12, 2024. The filing does not provide specific details about the agreement or any associated dollar amounts.
Why It Matters
This filing indicates a significant new contract or partnership for Pluri Inc., which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Pluri Inc. (company) — Registrant
- June 18, 2024 (date) — Report Date
- June 12, 2024 (date) — Earliest Event Date
FAQ
What is the nature of the material definitive agreement entered into by Pluri Inc.?
The filing states that Pluri Inc. entered into a material definitive agreement on June 12, 2024, but does not specify the details of this agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on June 12, 2024.
What is the SEC file number for this filing?
The SEC file number for this filing is 001-31392.
What is the state of incorporation for Pluri Inc.?
Pluri Inc. is incorporated in Nevada.
What is the SIC code for Pluri Inc.?
The Standard Industrial Classification (SIC) code for Pluri Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 768 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2024-06-18 07:00:32
Key Financial Figures
- $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
- $10,000,000 — fering, for aggregate gross proceeds of $10,000,000. As part of the Offering, Pluri agreed
- $1,250,000 — of the Offering, Pluri agreed to invest $1,250,000. The $10,000,000 funding round is inte
Filing Documents
- ea0207508-8k_pluri.htm (8-K) — 41KB
- ea020750801ex10-1_pluri.htm (EX-10.1) — 162KB
- ea020750801ex10-2_pluri.htm (EX-10.2) — 118KB
- 0001213900-24-053515.txt ( ) — 552KB
- plur-20240612.xsd (EX-101.SCH) — 3KB
- plur-20240612_lab.xml (EX-101.LAB) — 33KB
- plur-20240612_pre.xml (EX-101.PRE) — 22KB
- ea0207508-8k_pluri_htm.xml (XML) — 4KB
01. Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement. Share Purchase Agreement On June 12, 2024, Pluri Inc., or Pluri, entered into a share purchase agreement, or the Agreement, by and among Pluri's majority owned subsidiary, Ever After Foods Ltd., or Ever After, Tnuva Food-Tech Incubator (2019), Limited Partnership, or Tnuva, and certain other investors, or, collectively, the Investors, as referenced in exhibit 10.1 to this Current Report on Form 8-K, or this Report, pursuant to which Ever After agreed to issue and sell, ordinary shares in a private placement offering, or the Offering, for aggregate gross proceeds of $10,000,000. As part of the Offering, Pluri agreed to invest $1,250,000. The $10,000,000 funding round is intended to support Ever After's business-to-business (B2B) technology platform, positioning it as a sustainable technology enabler. Ever After is Pluri's majority-owned joint venture with Tnuva and has exclusive licensing rights to use Pluri's technology and intellectual property to develop, manufacture and commercialize cultivated meat. Following the closing of the Offering, Pluri will continue to own approximately 69% of Ever After. License Agreement On June 12, 2024, Pluri Biotech Ltd., Pluri's wholly owned subsidiary, and Ever After executed an Amended and Restated Technology License Agreement, dated June 12, 2024, or the Amended License. The Amended License amends the parties' existing license agreement dated as of February 23, 2022, to expand the scope of the license to include fish and seafood, and includes a waiver by Pluri of certain associated license royalties. The foregoing description of the Agreement and the Amended License are not complete and are qualified in their entirety by reference to the full text of the Agreement and the Amended License, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Report and are incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1^ Share Purchase Agreement, dated June 12, 2024, by and among Ever After and the Investors. 10.2 ^ Amended and Restated Technology License Agreement, dated June 12, 2024, between Pluri Biotech Ltd. and Ever After Foods Ltd. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). ^ Certain identified information in the exhibit has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to Pluri if publicly disclosed. Pluri agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. By: /s/ Chen Franco-Yehuda Name: Chen Franco-Yehuda Title: Chief Financial Officer Date: June 18, 2024 2